» Articles » PMID: 38443987

The Contribution of Pattern Recognition Receptor Signalling in the Development of Age Related Macular Degeneration: the Role of Toll-like-receptors and the NLRP3-inflammasome

Overview
Publisher Biomed Central
Date 2024 Mar 5
PMID 38443987
Authors
Affiliations
Soon will be listed here.
Abstract

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss, characterised by the dysfunction and death of the photoreceptors and retinal pigment epithelium (RPE). Innate immune cell activation and accompanying para-inflammation have been suggested to contribute to the pathogenesis of AMD, although the exact mechanism(s) and signalling pathways remain elusive. Pattern recognition receptors (PRRs) are essential activators of the innate immune system and drivers of para-inflammation. Of these PRRs, the two most prominent are (1) Toll-like receptors (TLR) and (2) NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3)-inflammasome have been found to modulate the progression of AMD. Mutations in TLR2 have been found to be associated with an increased risk of developing AMD. In animal models of AMD, inhibition of TLR and NLRP3 has been shown to reduce RPE cell death, inflammation and angiogenesis signalling, offering potential novel treatments for advanced AMD. Here, we examine the evidence for PRRs, TLRs2/3/4, and NLRP3-inflammasome pathways in macular degeneration pathogenesis.

Citing Articles

Molecular hybridization modification improves the stability and immunomodulatory activity of TP5 peptide.

Wang J, Tang Y, Zhao X, Ding Z, Ahmat M, Si D Front Immunol. 2024; 15:1472839.

PMID: 39588365 PMC: 11586334. DOI: 10.3389/fimmu.2024.1472839.


Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling.

Pallathadka H, Khaleel A, Zwamel A, Malathi H, Sharma S, Rizaev J Cell Biochem Biophys. 2024; 82(4):3015-3030.

PMID: 39110298 DOI: 10.1007/s12013-024-01418-2.

References
1.
Doyle S, Adamson P, Lopez F, Humphries P, Campbell M . Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat Med. 2014; 20(12):1376-7. DOI: 10.1038/nm.3741. View

2.
Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

3.
Piippo N, Korhonen E, Hytti M, Skottman H, Kinnunen K, Josifovska N . Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome. Sci Rep. 2018; 8(1):6720. PMC: 5928092. DOI: 10.1038/s41598-018-25123-2. View

4.
Zareparsi S, Buraczynska M, Branham K, Shah S, Eng D, Li M . Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum Mol Genet. 2005; 14(11):1449-55. DOI: 10.1093/hmg/ddi154. View

5.
Noailles A, Kutsyr O, Maneu V, Ortuno-Lizaran I, Campello L, de Juan E . The Absence of Toll-Like Receptor 4 Mildly Affects the Structure and Function in the Adult Mouse Retina. Front Cell Neurosci. 2019; 13:59. PMC: 6401850. DOI: 10.3389/fncel.2019.00059. View